TECOmedical Group

always your partner

Technical Information

PreKallikrein Activator

Chromogenic assay for the determination of Prekallikrein Activator (PKA) in Human Blood Products and Biologicals according to the European Pharmacopoeia.

Cat. No.:	PW301EP		
	PW51005	Just Positive PKA Control	5x0.5ml
	PW52005	High Positive PKA Control	5x0.5ml
Method:	**Chrom. Assay**		
Tests:	90		
Range:	1.56 – 25 IU/ml PreKallikrein Activator		
Sensitivity:	2.25 IU/ml (for standard protocol but higher if required)		
Incubation time:	45 minutes		
Sample volume:	100 µl (dilute 1:2)		
Sample type:	Plasma, serum, and fractionated plasma concentrates/finished preparation with level adjusted to below 50 IU/ml by dilution in albumin.		
Sample preparation:	Plasma should be prepared as soon as possible following collection. And if not tested immediately should be stored for 6 months at –20 °C or lower and should not be frozen/thawed again.		
Species:	Human and other mammalian species		
	Calibrated 2nd International reference preparation (NIBSC)		

Intended use:

The fractionation of Human plasma to produce Human Albumin and Immunoglobulin preparations for substitution therapy concentrates not only the preparations but also PKA which if present at high enough levels can release kallikrein and cause patients to go into shock. PKA is normally removed by post fractionation chromatography but this has to be validated so all Blood Product licensing authorities require manufacturers to measure PKA levels in each batch of final product before it can be released for patient care.
In the EU the requirements for this testing are outlined in the general monograph 'Human plasma for fractionation (0853)' of the European Pharmacopoeia (Ph. Eur.) and in the specific monograph 0255 Albumin solution and monograph 01/2006:0918 for Human immunoglobulin fractions. Further details are outlined within the framework of Article 114 Paragraph 2 of Directive 2001/83/EC and Article 1, paragraph 78 of the amending Directive 2004/27/EC and following the current Guideline on EC Administrative Procedure for Official Control Authority Batch Release.

The test involves the PKA present in the blood product being tested, activating Prekallikrein to release the enzyme Kallikrein. The Kallikrein released is measured using a synthetic peptide substrate for the enzyme which releases a chromogen that can be quantified using a microtitre plate reader. The critical components of the test are the Prekallikrein preparation which must not be activated before testing and the specificity of the chromogenic substrate for Kallikrein.

For further information please contact / Für weitere Informationen wenden Sie sich bitte an / Pour plus d´informations, veuillez contacter:

www.tecomedical.com

A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters
TECO*medical* AG
Gewerbestrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany
TECO*medical* GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux
TECO*medical* Benelux BV
Prins Willem-Alexanderlaan 301
7311 SW Apeldoorn, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria
TECO*medical* AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com

© 02/2021 | TECOmedical Group, Switzerland